Amgen reports positive data from new migraine drug trial

Amgen has announced the results of a phase III clinical trial showing the benefits of its new migraine therapy erenumab.

Data from the STRIVE study showed how the drug provided statistically significant reductions from baseline in monthly migraine days in patients with episodic migraine treated with erenumab, when compared with placebo.

Amgen's drug functions by blocking the calcitonin gene-related peptide receptor, which is believed to play a critical role in mediating the incapacitating pain caused by migraines.

The results from STRIVE reinforce the growing body of evidence supporting erenumab, which has been trialled among almost 2,200 patients with chronic and episodic migraine across three large-scale studies to date.

Dr Sean Harper, executive vice-president of research and development at Amgen, said: "We look forward to working with regulatory authorities to pursue approval of erenumab and making this novel migraine prevention treatment available to patients and physicians."

Erenumab is being co-developed by Amgen and Novartis, with applications for regulatory approval of the drug anticipated in 2017.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.